Critical Care Resources and Disaster Preparedness Survey 2020

Results

March 2021

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Authors

Professor Simon Finfer	The George Institute for Global Health, Critical Care Division, Australian Sepsis Network
Dr Naomi Hammond	The George Institute for Global Health, Critical Care Division, Australian Sepsis Network
Dr Bharath Kumar Tirupakuzhi Vijayaraghavan	Department of Critical Care Medicine, Apollo Hospitals, Chennai, India and Honorary Senior Fellow, The George Institute for Global Health, New Delhi, India.
Dr Lowell Ling	Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong, China
Dr Louise Thwaites	Oxford University Clinical Research Unit, Vietnam
Dr Brett Abbenbroek	The George Institute for Global Health, Critical Care Division and Australian Sepsis Network

This report was prepared on behalf of the Asia Pacific Sepsis Alliance a regional alliance of the Global Sepsis Alliance.

Contents

Abstract.....	4
Introduction	5
Method.....	5
Survey design.....	5
Survey administration	5
Results.....	6
Respondents	6
ICU staffing	8
ICU workforce roles	8
ICU diagnostics.....	9
Imaging	9
Pathology	10
ICU clinical care	12
Interventions.....	12
Monitoring	13
Pharma therapeutics	14
Intravenous fluids and medications.....	14
Antivirals and antimicrobials	15
Sepsis management	17
Evidence based guidelines	17
Quality and research	18
SARS-CoV2 and disaster preparedness	19
Resources and planning	19
Isolation and surge capacity	21
Conclusion	22
Appendix 1 Tables	23
References	30

Abstract

Aim: To investigate critical care resourcing and the clinical management of sepsis in lower-middle income, upper-middle income and high income countries across the Asia Pacific region.

Background: Sepsis is a time-critical complex condition that requires evidence-based care delivered by appropriate levels of well trained, qualified and experienced staff supported by proactive organisational and quality processes, sophisticated technologies and reliable infrastructure. In 2017, the estimated sepsis incidence in the Asia Pacific region ranged from 120 to 200 per 100,000 population in Australia and New Zealand to 2500 to 3400 per 100,000 population in India. Currently, there is limited information on the organisational structures, human resources, clinical standards, laboratory support and the therapeutic options available in the Asia Pacific region to treat sepsis.

Method: Prospective electronic survey.

Results: Representatives of 59 hospitals from 15 countries responded. Provision of critical care and the management of sepsis varied considerably between lower-middle income, upper-middle income and high income countries. Specific differences include nurse to patient ratios and availability of allied health services.

Conventional organ support modalities such as mechanical ventilation and non-invasive ventilation were commonly available. Even advanced life support like extracorporeal membrane oxygenation was available in at least 60% of surveyed ICUs. However, in contrast, essential monitoring devices including EtCO₂ were not universally available.

Lower-middle income countries had considerably lower provisions for isolation and surge capacity to support pandemic and disaster management, though basic personal protective equipment was widely available.

A majority of ICUs used the Surviving Sepsis Campaign guidelines or the adapted version for lower-middle income countries, though only 21% of ICUs in lower-middle income countries used the adapted version. While essential antimicrobials were accessible across most ICUs, availability of reserve antibiotics was limited.

Conclusion: The disparities identified in this survey inform healthcare workers and health services, policy makers and governments on the priorities for action to improve the delivery of critical care and sepsis outcomes in this region.

Keywords: critical care, disaster, resources, sepsis

Introduction

Sepsis is a time-critical complex condition that requires evidence-based care delivered by appropriate levels of well trained, qualified and experienced staff supported by proactive organisational and quality processes, sophisticated technologies and reliable infrastructure. In 2017, the estimated sepsis incidence in the Asia Pacific region ranged from 120 to 200 per 100,000 population in Australia to 2500 to 3400 per 100,000 population in India.¹

Currently, there is limited information on the organisational structures, human resources, clinical standards, laboratory support, and therapeutic options available in the Asia Pacific region to treat sepsis.² The Asia Pacific Sepsis Alliance (APSA), a regional network of the Global Sepsis Alliance (GSA), conducted a survey across the Asia Pacific including lower middle income (LMIC), upper middle income (UMIC) and high income countries (HIC) to better understand differences in critical care resources.³ The purpose of the survey is to inform healthcare workers, services, policy and governments, and facilitate improvements in sepsis care. The survey was conducted during the early phase of the COVID-19 pandemic, so included disaster management and questions specific to COVID-19 patients.

Method

Survey design

The electronic survey was adapted from a similar critical care resources survey designed by the Latin America Intensive Care Network⁴, and modified to suit regional needs. Survey development was iterative and was led by a working group of critical care clinicians and researchers from the region. The working group included representatives from both HICs and LMICs. Survey responses were predominantly limited to 'yes' or 'no' type answers with select questions requiring a quantitative response or a descriptive response. No free text responses were allowed. The draft survey was tested within the survey development group to ensure clarity, logical flow and timeliness. A participant information sheet administered along with the survey provided details of the aims of the survey, instructions for completion and information on consent. The survey was approved Chinese University of Hong Kong Survey and Behavioural Research Ethics (SBRE-19-565).

Survey administration

The survey was conducted between April 15, 2020 and June 1, 2020. Participants (frontline healthcare workers) were recruited by snowball sampling, first through the APSA network in each country and then through their contacts. Participants were invited by email to complete an online survey. Each respondent provided confirmation that they understood participation was voluntary and that survey completion implied consent for researchers to share and publish the data. The survey was administered using a commercial application- Survey Monkey (SurveyMonkey Inc. San Mateo, California, USA www.surveymonkey.com) and completion time ranged from 7 to 9 minutes. All deidentified survey data was stored on a secure server hosted by The Chinese University of Hong Kong.

Results

Survey results are presented in figures and the tabulated data provided in Appendix 1.

Respondents

Representatives of 59 hospitals from 15 countries responded (Figure 1) including 33 LMICs, eight UMICs and 18 HICs.

Figure 1 Participating ICUs according to country

The majority of hospitals were tertiary or university hospitals with ICUs capable of treating both adult and paediatric patients with level III facilities (Figure 2).

Figure 2 Hospital and ICU type (level)

A level I ICU is capable of providing oxygen, non-invasive monitoring, and more intensive nursing care than on a ward, whereas a level II ICU can provide invasive monitoring and basic life support for a short period.

A level III ICU provides a full spectrum of monitoring and life support technologies, serves as a regional resource for the care of critically ill patients, and may play an active role in developing the specialty of intensive care through research and education.⁵

The majority were large hospitals (median 798 beds, range 50-2000) with a median of 37 (range 3-200) ICU beds and a median of 3000 (range 432-10,000) admissions annually.

Organisational attributes of the hospitals and ICUs are shown in Appendix 1, Table 1 by income group.

ICU staffing

Staffing to patient ratios for Doctors and Nurses are summarised in Figure 3.

Figure 3 Staff to patient ratios in participating ICUs, Asia Pacific region
(NB. V = ventilated, NV = non-ventilated)

Median doctor and nurse to patient ratios are similar across income groups, and all units showed generally reduced staffing numbers at night. Whilst doctor to patient ratios were similar across all income settings, nurse to patient ratios showed a much greater variation, with up to 8 patients per nurse in LMIC ICUs (Table 1).

ICU workforce roles

Essential roles including an Intensivist, Physiotherapist, Pharmacist, Nutritionist and Social Worker were available in a majority of ICU's across the region (Figure 4, Table 1). However, 24/7 access to a physiotherapist was limited in a majority of ICUs in the region.

Figure 4 ICU workforce roles, Asia Pacific region

All high and middle income units reported access to physiotherapy (including 24/7 access in 31% of HIC units), while 19% of LMIC reported they had no physiotherapy available in ICU (Figure 5, Table 2).

Figure 5 ICU role availability according to country income group

ICU diagnostics

Imaging

Standard diagnostic imaging modes were available in all settings (Figure 6, Table 3).

Figure 6 ICU access to different imaging modalities, Asia Pacific region

Limited availability of diagnostic imaging was particularly evident in lesser resourced LMICs (Figure 7, Table 3).

Figure 7 ICU diagnostic imaging availability per income group

Pathology

Almost all sites reported 24 hour laboratory availability (92%) and point-of-care testing for arterial blood gases (92%), lactate (68%) and glucose (96%) in the ICU itself (Figure 8, Table 4). Microbiology was also broadly available in ICUs (94%) and offered diagnostic capability for locally relevant pathogens such as dengue and malaria.

Figure 8 Diagnostic pathology availability in participating ICUs, Asia Pacific region

Limited access to viral PCR, procalcitonin and C-Difficile testing was evident in UMIC and LMIC ICUs, and less than 50% of LMIC ICUs could access toxicology services (Figure 9, Table 4). Overall, more UMIC ICU's had the most types of diagnostic pathology testing available.

Figure 9 ICU diagnostic pathology availability per income group

The median time for a RT PCR SARS-coV2 test result across the region was 450 min (range 50-14440).

Both HIC and UMIC ICUs reported a shorter median time for a RT PCR SARS-coV2 test result with both income categories taking 360 min, ranging from 50 to 2880 and 60 to 2880 min respectively. In contrast, LMIC ICU's reported a longer median test result time of 1080 min (range 240-14440).

ICU clinical care

Interventions

Respiratory support modalities were relatively consistent across the region with greater variation in the availability of extracorporeal therapies in ICU including ECMO (62%), CRRT (70%) and plasmapheresis (77%) (Figure 10, Table 5).

Figure 10 Clinical intervention availability in participating ICUs across the Asia Pacific region

Availability of ICU interventions was similar across income groups except for continuous renal replacement therapy which was only available in 50% LMICs compared to 100% and 80% in HIC and UMIC respectively (Figure 11, Table 5).

Figure 11 ICU clinical interventions availability according to country income group

Nevertheless, all ICUs had some form of renal replacement therapy available as either continuous renal replacement therapy or haemodialysis. More complex therapies, such as ECMO, were more available in HIC ICUs (86%) compared to UMIC (60%) and LMIC (46%) ICUs.

Monitoring

Cardiorespiratory physiological monitoring modalities such as ECG, intra-arterial pressure, central venous pressure (CVP), pulse oximetry (SpO_2) and end tidal carbon dioxide (E_TCO_2) monitoring were standard in around 80% or more of the ICUs across the region (Figure 12, Table 6).

Figure 12 Availability of monitoring modalities in participating ICUs, Asia Pacific region

While more complex modalities such as cardiac output measurement, intra-abdominal pressure and intracranial pressure monitoring were only available within approximately half of the ICUs.

Significant differences were evident between income groups in the use of cardiac output measurement, intraabdominal pressure and intracranial pressure with only 40% or less of ICUs in UMIC and LMICs having access to these modalities (Figure 13, Table 6).

Figure 13 ICU physiological monitoring availability according to country income group

Pharma therapeutics

Intravenous fluids and medications

The availability of intravenous crystalloids, colloids, vasoactive drugs and hydrocortisone in ICU was similar across the region (Figure 14, Table 7).

Figure 14 Access to intravenous fluids and medications in participating ICUs, Asia Pacific region

The availability of intravenous crystalloids, colloids, vasoactive drugs and hydrocortisone in ICU was similar across the three income groups with between 85% and 100% of ICUs able to access these resources (Figure 15, Table 7).

Figure 15 ICU intravenous fluids and medications available according to country income group

Antivirals and antimicrobials

The availability of antivirals varied widely depending on the drug in question with only 12% of ICUs reporting access to Remdesevir compared to 88% reporting access to Hydroxychloroquine (Figure 16, Table 8).

Figure 16 Access to antivirals and antimicrobials in participating ICUs, Asia Pacific region

A wide variety of antimicrobials, listed as essential medicine by the World Health Organisation (WHO) such as gentamicin and amoxicillin and cefuroxime, were available in most units across the region. However, “reserve” antimicrobials classified in the WHO Access, Watch, and Reserve (AWaRE) tool⁶, such as Ceftazidime Avibactam, Minocycline and Fosfomycin, were limited.

Antiviral availability across income groups was similar though UMIC and LMIC ICUs had limited to no access to Remdesevir, 0% and 4% respectively, with LMIC having the best access to Hydro chloroquine (93%) (Figure 17, Table 8).

Figure 17 Antiviral and antimicrobial availability according to country income group

LMICs in general had less availability of antimicrobials than HIC but ICU's in UMIC recorded the lowest access to a number of antimicrobials including Ceftaz-Avibactam (20%), Tigecycline (60%), Minocycline (20%), Polymyxin (40%) and Linezolid (40%).

Sepsis management

Evidence based guidelines

Sepsis specific management guidelines were used broadly across the region, with 86% of ICUs reporting the availability of international, national, state/region and unit specific guidelines (Figure 18, Table 18). Despite the large proportion of LMIC in the survey only 14% of ICUs overall used the tailored LMIC sepsis management guidelines. Clinicians reported sufficient resources and training to adhere to guidelines in 78% of ICU's .

Figure 18 Sepsis guidelines used and adherence in participating ICUs, Asia Pacific region

More UMIC (100%) and LMIC ICU's (92%) had sepsis guidelines in place than HIC ICU's (67%). The Surviving Sepsis Campaign (SSC) guidelines were most commonly used across all income groups (Figure 19, Table 9).

Figure 19 Sepsis guidelines in use according to country income group

There was relatively poor uptake of the SCC COVID-19 guidelines in HIC (55%) and UMIC (17%) ICUs compared to LMIC ICUs (71%). In contrast to expectations, only 21% of LMIC ICU's were using the adapted SSC guidelines for LMIC's, which were not used UMIC and only 14% of HIC ICU's. Around 30-40% of all income groups used a national guideline for sepsis management.

Quality and research

Infection control policies and antimicrobial stewardship programs (AMS) were available in 98% and 88% of units respectively (Figure 20, Table 10). However, only 56% of responding ICUs reported the availability of a specific sepsis consultation service available. Unit based and multicentre research was conducted in 65% and 52% respectively.

Figure 20 Quality improvement and research in participating ICUs, Asia Pacific region

Infection control policies and AMS programs operated in ICUs across all income groups (Figure 21, Table 10). Routine infectious team consult for sepsis patients was not as ubiquitous with only 17% of UMIC ICU's having adopted this quality strategy compared to HIC (63%) and LMIC (62%) ICU's. A similar proportion of ICU's conducted unit-based research across all income groups (range 62%-69%) but UMIC reported considerably less multicentre research (17%), industry sponsored research (17%) and RCT's (33%).

Figure 21 Quality improvement and research according to country income group

SARS-CoV2 and disaster preparedness

Resources and planning

All units reported a good availability of basic equipment (Personal protection equipment, N95 masks, gloves, alcohol gel) (Figure 22, Table 11).

Figure 22 Resourcing for disaster management in participating ICUs, Asia Pacific region

Personal protection equipment (PPE) for disaster management was readily accessible across all income groups (Figure 23, Table 11) other than air purifying equipment which was available in only half of HIC and UMIC ICU's and only 25% of LMIC ICU's.

Figure 23 Disaster management resources according to country income group

A majority of respondents had a disaster plan (98%) that included guidelines or training for use of PPE (95%) and patient triage screening and isolation (93%) (Figure 24, Table 12). Bed surge and workforce management were both included in 97% of plans but only 71% included triage surge guidelines and 75% involved simulation training.

Figure 24 Disaster plan components across participating ICUs, Asia Pacific region

Hospital disaster plans addressed PPE use, screening and isolation, surge management and training across all income groups (Figure 25, Table 12). Fewer plans included surge triage guidelines in HIC (67%) and UMIC (63%) hospitals than in LMIC's (76%), and considerably less HIC hospitals conducted training (67%) than UMIC (88%) and LMIC (76%) hospitals.

Figure 25 Disaster planning components and preparation according to country income group

Isolation and surge capacity

Across the region there was a median of nine single hospital rooms (range 1-25) and seven single ICU rooms (range 1-25) reported (Figure 26, Table 13).

Figure 26 Isolation and surge capacity in participating hospitals, Asia Pacific region

The LMIC group reported considerably less hospital and ICU isolation capacity, median 7 beds and 5.5 beds respectively (Figure 27, Table 13). This was also evident for hospital and ICU negative pressure rooms with a median of 4 rooms and 2 rooms respectively in LMICs, approximately half that of UMIC and one quarter or less capacity than in HIC's. Across the region there was a median surge capacity of 10 ICU beds (range 0-120) reported though the median for HIC's was 17 surge ICU beds. Peak ventilation capacity was relatively similar for all income groups with a median of 49 (range 0-250) mechanical ventilators.

Figure 27 Isolation and surge capacity according to country income group

Conclusion

Although this survey mostly sampled tertiary ICUs across HICs and LMICs, provision of critical care for management of sepsis varied across the Asia Pacific region. Specific differences include nurse to patient ratios and availability of allied health services.

Conventional organ support modalities such as mechanical ventilation and non-invasive ventilation were commonly available. Even advanced life support like ECMO was available in at least 60% of surveyed ICUs. However, in contrast, essential monitoring devices like EtCO₂ were not universally available.

In terms of pandemic and disaster planning, whilst basic personal protective equipment was widely available, LMICs had much lower provisions for isolation and surge capacity. Most ICUs use the SSC guidelines or the adapted SSC guidelines for LMICs, though only 21% of LMIC ICU's used the adapted version of the SSC guidelines. Essential antimicrobials are accessible across most ICUs in the region, but availability of reserve antibiotics was limited.

The disparities identified in this survey provide priorities for action to improve sepsis outcomes in this region.

Appendix 1 Tables

Table 1 Hospital and ICU characteristics per income group

Hospital	All				High Income				Upper Middle Income				Lower Middle Income			
	N ¹	Count	Median	% or (range)	N	Count	Median	% or (range)	N	Count	Median	% or (range)	N	Count	Median	% or (range)
Adult		9		15		3		17		1		6		5		15
Adult & Paediatric	59	50		85	18	15		83	8	7		39	33	28		85
Community		3		1		0		0		0		0		3		1
Regional	59	11		19	18	6		33	8	1		13	33	4		12
Tertiary		45		76		12		67		7		87		26		79
ICU level 1	59	3		1	18	0		0	8	0		0	33	3		9
ICU level 2	59	12		23	18	1		6	8	1		6	33	10		30
ICU level 3	59	44		76	18	17		94	8	7		39	33	20		61
Hospital beds	59		798	(50-2000)	18		1186	(304-2000)	8		1000	(122-2000)	33		599	(50-2000)
ICU beds	59		37	(3-200)	18		50	(15-200)	8		49	(10-170)	33		35	(3-103)
HDU beds	59		25	(0-200)	18		22	(0-102)	8		35	(0-66)	33		20	(0-200)
Annual ICU admissions	49		3000	(432-10000)	15		3510	(1138-10000)	7		3429	(1005-10000)	27		2495	(432-10000)
Day shift Ratio Pt ² to Dr	48		5	(1-25)	16		4	(1-25)	6		4	(3-10)	26		5	(1-20)
Night shift Ratio Pt to Dr	48		9.5	(1-25)	16		10	(1-25)	6		8	(6-25)	26		9.5	(1-30)
Day shift Ratio ventilated Pt to Nurse	48		2	(1-8)	16		1	(1-2)	6		2	(1-2)	26		2	(1-8)
Night shift Ratio ventilated Pt to Nurse	48		2	(0-8)	16		2	(0-2)	6		3	(1-4)	26		2	(1-8)
Day shift Ratio non-vent Pt to Nurse	48		2	(0-50)	16		2	(0-4)	6		2	(1-5)	26		2.5	(1-50)
Night shift Ratio non-vent Pt to Nurse	48		2	(0-50)	16		2	(0-4)	6		3	(1-4)	26		3	(1-50)

1. N = survey responses; 2. Pt = patient

Table 2 ICU role availability per income group

	All			High Income			Upper Middle Income			Lower Middle Income		
	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)
Intensivist every shift	48	33	69	16	12	75	6	3	50	26	18	69
No physiotherapy available	48	5	10	16	0	0	6	0	0	26	5	19
Physiotherapy limited	48	37	77	16	11	69	6	6	100	26	20	77
Physiotherapy 24/7	48	6	13	16	5	31	6	0	0	26	1	4
Pharmacist	48	37	77	16	13	81	6	4	67	26	20	77
Nutritionist	46	41	89	16	15	94	6	5	83	24	21	88
Social worker	48	31	65	16	12	75	6	3	50	26	16	62

* indicates median

Table 3 ICU diagnostic imaging availability per income group

	All			High Income			Upper Middle Income			Lower Middle Income		
	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)
Portable CXR 24/7	47	44	94	16	14	88	5	5	100	26	25	96
Limited portable CXR	47	3	6	16	2	12	5	0	0	26	1	4
CT 24/7	47	39	83	16	13	81	5	5	100	26	21	81
Limited CT	47	7	15	16	2	12	5	0	0	26	5	19
Ultrasound 24/7	47	38	81	16	14	88	5	5	100	26	19	73
Limited ultrasound	47	9	19	16	2	13	5	0	0	26	7	27
MRI 24/7	47	26	55	16	8	50	5	3	60	26	15	58
Limited MRI	47	17	36	16	8	50	5	1	20	26	8	31
No MRI	47	4	9	16	0	0	5	1	20	26	3	12

* indicates median

Table 4 ICU diagnostic pathology availability per income group

	All			High Income			Upper Middle Income			Lower Middle Income		
	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)
Viral PCR	47	35	75	16	16	100	5	3	60	26	16	62
RT PCR SARS-CoV2	52	36	69	16	12	75	8	7	88	28	17	61
Time RT PCR (min)	51	450*	(50-14440)	15	360*	(50-2880)	8	360*	(60-2880)	28	1080*	(240-14440)
POC ABG	47	43	92	16	15	94	5	5	100	26	23	89
POC Lactate	47	32	68	16	11	69	5	4	80	26	17	65
PCO glucose	47	45	96	16	16	100	5	5	100	26	24	92
Lab 24/7	47	44	94	16	15	94	5	5	100	26	24	92
Haem-FBC	47	46	98	16	15	100	5	5	100	26	26	100
Haem-coagulation	47	47	100	16	16	100	5	5	100	26	26	100
Biochemistry	47	45	96	16	15	94	5	5	100	26	25	96
Procalcitonin	46	38	83	16	15	94	4	3	75	26	20	77
Microbiology	47	44	94	16	14	88	5	5	100	26	25	96
Thrombo-elastogram	47	20	43	16	7	44	5	1	20	26	12	46
Toxicology	47	29	62	16	12	75	5	4	80	26	13	50
Malaria	47	37	78	16	12	75	5	5	100	26	20	77
TB	47	42	89	16	14	88	5	5	100	26	23	89
Dengue	47	40	85	16	10	63	5	5	100	26	25	96
Ebola	47	7	15	16	6	38	5	0	0	26	1	96
C.difficile	47	33	70	16	15	94	5	3	60	26	15	58
Blood culture	47	45	96	16	15	94	5	5	100	26	25	96

* indicates median

Table 5 ICU clinical interventions performed per income group

	All			High Income			Upper Middle Income			Lower Middle Income		
	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)
Oxygen therapy	47	45	96	16	15	94	5	5	100	26	25	96
High flow nasal oxygen	47	33	70	16	16	100	5	4	80	26	13	50
Non-invasive ventilation	47	46	98	16	16	100	5	5	100	26	25	96
Mechanical ventilation	47	46	98	16	15	94	5	5	100	26	26	100
Extracorporeal Membrane Oxygenation	47	29	62	16	14	86	5	3	60	26	12	46
Continuous Renal Replacement Therapy	47	33	70	16	16	100	5	4	80	26	13	50
Haemodialysis	47	45	96	16	14	88	5	5	100	26	26	100
Plasmapheresis	47	36	77	16	14	60	5	3	73	26	19	77
Percutaneous Tracheostomy	46	38	83	15	13	87	5	3	60	26	22	85
Fibreoptic Bronchoscopy	47	40	85	16	15	94	5	4	80	26	21	81

* indicates median

Table 6 ICU physiological monitoring availability per income group

	All			High Income			Upper Middle Income			Lower Middle Income		
	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)
Electrocardiogram	47	45	96	16	15	94	5	5	100	26	25	96
Intra-arterial Pressure	47	42	90	16	16	100	5	4	80	26	22	85
Central Venous Pressure	47	39	83	16	14	88	5	4	80	26	21	81
Echocardiography	47	45	96	16	16	100	5	5	100	26	24	92
Pulse Oximetry	47	46	98	16	15	94	5	5	100	26	26	100
End Tidal CO ₂	47	37	78	16	15	94	5	5	100	26	17	65
Cardiac Output	47	25	54	15	13	87	5	2	40	26	10	39
Intra-abdominal Pressure	45	25	56	15	12	80	5	2	40	25	11	44
Electroencephalogram	46	31	67	15	12	80	5	3	60	26	16	62
Intra-cranial Pressure	47	24	51	16	15	94	5	2	40	26	7	27

* indicates median

Table 7 ICU intravenous fluids and medications availability per income group

	All			High Income			Upper Middle Income			Lower Middle Income		
	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)
Balanced crystalloids	47	46	98	16	16	100	5	5	100	26	25	96
Non-balanced crystalloids	47	46	98	16	16	100	5	5	100	26	25	96
Albumin	47	45	96	16	16	100	5	5	100	26	24	92
Other colloids	47	41	87	16	14	88	5	5	100	26	22	85
Vasoactive Drugs	47	47	100	16	16	100	5	5	100	26	26	100
Hydrocortisone	47	47	100	16	16	100	5	5	100	26	26	100

* indicates median

Table 8 Antiviral and antimicrobial availability per income group

		All			High Income			Upper Middle Income			Lower Middle Income		
		N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)
Antivirals	Remdesevir	51	6	12	16	5	31	8	0	0	27	1	4
	Ribavirin	51	24	47	16	10	63	8	5	63	27	9	33
	Lopinavir/ritonavir	51	35	69	16	12	75	8	7	88	27	16	59
	Hydroxychloroquine	51	45	88	16	13	81	8	7	88	27	25	93
Antimicrobials	Ceftaz-Avibactam	46	26	57	15	11	73	5	1	20	26	14	54
	Tigecycline	45	31	69	14	9	64	5	3	60	26	19	73
	Minocycline	47	27	57	16	13	81	5	1	20	26	13	50
	Fosfomycin	46	25	54	15	7	47	5	3	60	26	15	58
	Polymyxin	47	35	75	16	12	75	5	2	40	26	21	81
	Echinocandins (e.g. Micafungin)	47	32	68	16	14	88	5	3	60	26	15	58
	Azole (e.g. Fluconazole)	47	43	92	16	14	88	5	4	80	26	25	96
	Oxazolidinones (e.g. Linezolid)	47	40	85	16	15	94	5	2	40	26	23	89
	Glycopeptides (e.g. Vancomycin)	49	45	96	16	15	94	5	4	80	26	26	100
	Carbapenems (e.g. Meropenem)	47	46	98	16	16	100	5	4	80	26	26	100
	Aminoglycoside (e.g. Gentamicin)	47	44	94	16	15	94	5	4	80	26	25	96
	Anti-pseudo Beta lactam	47	45	96	16	15	94	5	5	100	26	25	96
	Cephalosporin (e.g. Cefuroxime, Cefalexin)	47	46	98	16	15	94	5	5	100	26	26	100
	Penicillin	47	46	98	16	15	94	5	5	100	26	26	100

* indicates median

Table 9 Sepsis Guidelines per Income Group

	All			High Income			Upper Middle Income			Lower Middle Income		
	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)
Sepsis guideline (any)	42	36	86	12	8	67	6	6	100	24	22	92
Surviving Sepsis Campaign	41	31	76	12	8	67	6	5	83	23	18	78
Surviving Sepsis Campaign (COVID-19)	42	23	55	12	5	42	6	1	17	24	17	91
Sepsis management in LMIC	42	6	14	16	1	8	6	0	0	24	5	21
National guideline	42	15	36	12	5	42	6	2	33	24	8	33
State/regional guideline	42	1	2	12	1	8	6	0	0	24	0	0
Unit specific guideline	42	7	17	12	3	25	6	1	17	24	3	13

* indicates median

Table 10 Quality improvement activities and clinical research per income group

	All			High Income			Upper Middle Income			Lower Middle Income		
	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)
Infection control policies	48	47	98	16	16	100	6	6	100	26	25	96
AMS program	48	42	88	16	14	88	6	6	100	26	22	85
Sepsis consult (routine)	58	27	56	16	10	63	6	1	17	26	16	62
Unit-based research	58	31	65	16	11	69	6	4	67	26	16	62
Research publications	58	23	48	16	11	69	4	2	33	26	10	39
Multicentre research	48	25	52	16	10	63	6	1	17	26	14	54
Industry research	48	16	33	16	7	44	6	1	17	26	8	31
RCT's	48	22	46	16	9	56	6	2	33	26	11	42

* indicates median

Table 11 Disaster Management Resources per Income Group

	All			High Income			Upper Middle Income			Lower Middle Income		
	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)
Eye/face shields	59	56	95	18	16	89	8	8	100	33	32	97
N95	51	48	94	16	16	100	7	7	100	28	25	89
Gown	51	49	96	16	15	94	7	7	100	28	27	96
Gloves	51	50	98	16	16	100	7	7	100	28	27	96
Respirator/purifier	51	18	35	16	7	44	7	4	57	28	7	25
Alcohol hand hygiene	51	51	100	16	16	100	7	7	100	28	28	100

* indicates median

Table 12 Disaster planning components and preparation per income group

	All			High Income			Upper Middle Income			Lower Middle Income		
	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)	N	Count or median*	% or (range)
PPE guidelines	59	56	95	18	16	89	8	8	100	33	32	97
Screening and isolation guidelines	59	55	93	18	15	83	8	8	100	33	32	97
Surge management	59	57	97	18	16	89	8	8	100	33	33	100
Surge triage guidelines	59	42	71	18	12	67	8	5	63	33	25	76
Workforce/ staffing	59	57	97	18	17	94	8	8	100	33	32	97
Training/simulation	59	44	75	18	12	67	8	7	88	33	25	76

* indicates median

Table 13 Isolation and surge capacity per income group

	All			High Income			Upper Middle Income			Lower Middle Income		
	N	Median	% or (range)	N	Median	% or (range)	N	Median	% or (range)	N	Median	% or (range)
Single room hospital	59	9	(1-25)	18	12.5	(1-25)	8	11.5	(9-16)	33	7	(1-23)
Single room ICU	51	7	(1-25)	16	10.5	(4-25)	7	10	(3-23)	28	5.5	(1-20)
Negative pressure room hospital	48	7	(1-19)	14	12	(6-19)	7	5	(1-13)	27	4	(1-16)
Negative pressure room ICU	50	4	(1-13)	16	6.5	(3-13)	7	4	(1-11)	27	2	(1-12)
Surge beds	49	10	(0-120)	16	17	(0-120)	7	10	(4-40)	26	10	(0-60)
Peak ICU bed capacity	46	49	(0-215)	15	36	(0-215)	7	70	(10-200)	23	49	(10-150)
Peak ventilator capacity	48	49	(0-250)	15	32	(10-250)	7	40	(12-250)	26	50	(5-90)

References

1. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. *The Lancet*. 2020;395(10219):200-211.
2. Dondorp AM, Dünser MW, Schultz MJ. *Sepsis Management in Resource-limited Settings*. Springer Nature; 2019.
3. Al-Orainan N, El-Shabasy AM, Al-Shanqiti KA, et al. Public Awareness of Sepsis Compared to Acute Myocardial Infarction and Stroke in Jeddah, Saudi Arabia: Questionnaire Study. *Interactive Journal of Medical Research*. 2020;9(2):e16195.
4. Castro R, Nin N, Ríos F, et al. The practice of intensive care in Latin America: a survey of academic intensivists. *Critical Care*. 2018;22(1):1-11.
5. Marshall JC, Bosco L, Adhikari NK, et al. What is an intensive care unit? A report of the task force of the World Federation of Societies of Intensive and Critical Care Medicine. *Journal of Critical Care*. 2017;37:270-276.
6. WHO AWARE Antibiotic Categorisation. WHO; 2021.
<https://aware.essentialmeds.org/groups>. Accessed October 2020.